Castle Biosciences approved for dual listing on Nasdaq Texas

Castle Biosciences, Inc. (Nasdaq: CSTL) has been approved for a dual listing of its common stock on Nasdaq Texas, LLC, effective August 17, 2026. The company's common stock, which is already listed on The Nasdaq Global Market, will now also trade on Nasdaq Texas under the same ticker symbol "CSTL". This move follows the company's filing of a Registration Statement on Form 8-A with the U.S. Securities and Exchange Commission (SEC) to register its common stock for listing on Nasdaq Texas.

The dual listing is expected to enhance the liquidity and accessibility of Castle Biosciences' shares, providing additional opportunities for investors. The company's common stock description, as included in its Annual Report on Form 10-K for the year ended December 31, 2019, remains applicable and is incorporated by reference in the Form 8-A filing.

This development aligns with Castle Biosciences' ongoing efforts to strengthen its market presence and support its mission of improving health through innovative diagnostic tests. The dual listing does not alter the company's existing capital structure or shareholder rights.